Safety, Tolerability, and Efficacy of Darunavir (TMC114) with Low-Dose Ritonavir in Treatment-Experienced, Hepatitis B or C Co-infected Patients in POWER 1 and 3

Safety, Tolerability, and Efficacy of Darunavir (TMC114) with Low-Dose Ritonavir in Treatment-Experienced, Hepatitis B or C Co-infected Patients in POWER 1 and 3

Item
http://www.wikidata.org/entity/Q57880260
Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C coinfection: data from the ICONA foundation cohort.Darunavir : a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection.Profile of darunavir in the management of treatment-experienced HIV patientsDarunavir and ritonavir total and unbound plasmatic concentrations in HIV-HCV-coinfected patients with hepatic cirrhosis compared to those in HIV-monoinfected patientsCIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and TreatmentCIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults.Darunavir: an effective protease inhibitor for HIV-infected patients.Role of darunavir in the management of HIV infection.Darunavir: a review of its use in the management of HIV-1 infection.Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection.Hepatic safety profile of fosamprenavir-containing regimens in HIV-1-infected patients with or without hepatitis B or C coinfection.
P2860

Safety, Tolerability, and Efficacy of Darunavir (TMC114) with Low-Dose Ritonavir in Treatment-Experienced, Hepatitis B or C Co-infected Patients in POWER 1 and 3

Item
http://www.wikidata.org/entity/Q57880260
description
article
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2007
@uk
name
Safety, Tolerability, and Effi ...... cted Patients in POWER 1 and 3
@en
Safety, Tolerability, and Effi ...... cted Patients in POWER 1 and 3
@nl
type
label
Safety, Tolerability, and Effi ...... cted Patients in POWER 1 and 3
@en
Safety, Tolerability, and Effi ...... cted Patients in POWER 1 and 3
@nl
prefLabel
Safety, Tolerability, and Effi ...... cted Patients in POWER 1 and 3
@en
Safety, Tolerability, and Effi ...... cted Patients in POWER 1 and 3
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
Safety, Tolerability, and Effi ...... cted Patients in POWER 1 and 3
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698